Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1D | P25100 | 1/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 1/20 | 1.00 |
| ▸ | ADRA1B | P35368 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | MAOB | P27338 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9669562 | 0.93 | ADRA1D (0.87) | ADRA1DADRA1AADRA1BKMT2AMAOB | |
| SCHEMBL9669522 | 0.93 | ADRA1D (0.87) | ADRA1DADRA1AADRA1BKMT2AMAOB | |
| Abanoquil SCHEMBL3672975 | 0.92 | ADRA1D (0.85) | ADRA1DADRA1AADRA1BKMT2AMAOB | |
| Hydrochloric Acid SCHEMBL9670264 | 0.92 | ADRA1D (0.85) | ADRA1DADRA1AADRA1BKMT2AMAOB | |
| Abanoquil SCHEMBL29711625 | 0.92 | ADRA1D (0.85) | ADRA1DADRA1AADRA1BKMT2AMAOB | |
| Abanoquil SCHEMBL8856969 | 0.89 | ADRA1D (0.80) | ADRA1DADRA1AADRA1BKMT2AMAOB | |
| SCHEMBL9669930 | 0.87 | ADRA1D (0.76) | ADRA1DADRA1AADRA1BKMT2A | |
| SCHEMBL9667835 | 0.87 | ADRA1D (0.76) | ADRA1DADRA1AADRA1BKMT2A | |
| SCHEMBL24177242 | 0.81 | ADRA1D (0.68) | ADRA1DADRA1AADRA1B | |
| SCHEMBL7005481 | 0.81 | ADRA1D (0.67) | ADRA1DADRA1AADRA1BKMT2AMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 701 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250186415-A1 | EXTENDED-RELEASE PHARMACEUTICAL COMPOSITIONS FOR TREATING EYE CONDITIONS | FIFTH THIRD BANK, NATIONAL ASSOCIATION, AS AGENT | 2025-06-12 | — | — | US | claimed |
| EP-4489858-A1 | EXTENDED-RELEASE PHARMACEUTICAL COMPOSITIONS FOR TREATING EYE CONDITIONS | Harrow IP, LLC (US) | 2025-01-15 | — | — | EP | claimed |
| WO-2023172240-A1 | EXTENDED-RELEASE PHARMACEUTICAL COMPOSITIONS FOR TREATING EYE CONDITIONS | HARROW IP, LLC (US) | 2023-09-14 | — | — | WO | claimed |
| US-20220034911-A1 | METHOD OF MITIGATION OF DEATH FROM EPILEPTIC SEIZURES | VEGA JOSE (US) | 2022-02-03 | — | — | US | claimed |
| US-20220000871-A1 | METHODS AND COMPOSITIONS FOR TREATING NEURODEGENERATIVE DISEASES USING MODULATORS OF PHOSPHOGLYCERATE KINASE 1 (PGK1) ACTIVITY | UNIVERSITY OF IOWA RESEARCH FOUNDATION | 2022-01-06 | — | — | US | claimed |
| US-20210137854-A1 | TAAR Receptor Agonists for the Treatment of Alopecia | JUPITER WELLNESS INC. | 2021-05-13 | — | — | US | claimed |
| WO-2020055762-A1 | METHOD OF MITIGATION OF DEATH FROM EPILEPTIC SEIZURES | VEGA JOSE (US) | 2020-03-19 | — | — | WO | claimed |
| WO-2020023084-A1 | TAAR RECEPTOR AGONISTS FOR THE TREATMENT OF ALOPECIA | APPLIED BIOLOGY, INC. (US) | 2020-01-30 | — | — | WO | claimed |
| US-9585884-B2 | Pyrimidinone inhibitors of lipoprotein-associated phospholipase A2 | AUSPEX PHARMACEUTICALS, INC. (US) | 2017-03-07 | — | — | US | claimed |
| US-20170002015-A1 | CYCLOPROPYL MODULATORS OF P2Y12 RECEPTOR | AUSPEX PHARMACEUTICALS INC (US) | 2017-01-05 | — | — | US | claimed |
| EP-1018879-A1 | NITROSATED AND NITROSYLATED ALPHA-ADRENERGIC RECEPTOR ANTAGONIST COMPOUNDS, COMPOSITIONS AND THEIR USES | Nitromed, Inc. (US) | 2000-07-19 | — | — | EP | claimed |
| WO-2000012075-A1 | NITROSATED AND NITROSYLATED ALPHA-ADRENERGIC RECEPTOR ANTAGONISTS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2000-03-09 | — | — | WO | claimed |
| WO-1999030697-A2 | COMBINATION EFFECTIVE FOR THE TREATMENT OF IMPOTENCE | PFIZER PRODUCTS INC. (US) | 1999-06-24 | — | — | WO | claimed |
| EP-0799619-A2 | Use of alpha1-adrenoreceptor antagonists in the manufacture of a medicament for the prevention and treatment of benign prostatic hyperplasia | PFIZER INC. (US) | 1997-10-08 | — | — | EP | claimed |
| EP-0799618-A2 | Use of alpha1-adrenoreceptor antagonists in the manufacture of a medicament for the prevention and teatment of cancer | PFIZER INC. (US) | 1997-10-08 | — | — | EP | claimed |
| WO-1997027749-A1 | NITROSATED AND NITROSYLATED α-ADRENERGIC RECEPTOR ANTAGONIST COMPOUNDS, COMPOSITIONS AND THEIR USES | NITROMED, INC. (US) | 1997-08-07 | — | — | WO | claimed |
| EP-0183975-B1 | 5,6,7,8-TETRAFLUOROANTHRAQUINONE DERIVATIVES | Nippon Shokubai Kagaku Kogyo Co., Ltd (JP) | 1992-01-29 | — | — | EP | claimed |
| US-4686228-A | Quinoline therapeutic agents | PFIZER INC. (US) | 1987-08-11 | — | — | US | claimed |
| EP-0100200-B1 | 2-SUBSTITUTED 4-AMINO-6,7-DIMETHOXYQUINOLINES | Pfizer Limited (GB) | 1987-05-06 | — | — | EP | claimed |
| EP-0100200-A1 | 2-Substituted 4-amino-6,7-dimethoxyquinolines | Pfizer Limited (GB) | 1984-02-08 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170002015-A1 | CYCLOPROPYL MODULATORS OF P2Y12 RECEPTOR | P2RY12, P2RY11, P2RY2 | ADRA1D 329/4885ADRA1A 236/4885ADRA1B 223/4885 |
| US-20220000871-A1 | METHODS AND COMPOSITIONS FOR TREATING NEURODEGENERATIVE DISEASES USING MODULATORS OF PHOSPHOGLYCERATE KINASE 1 (PGK1) ACTIVITY | PYGB, PGK1, PGK2 | ADRA1D 3815/4885ADRA1A 3002/4885ADRA1B 3331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.